GENERAL
Morepen Laboratories Sharpens API Focus, Enters CDMO Growth Lane
Morepen Laboratories is strengthening its position in the global Active Pharmaceutical Ingredients (API) market while expanding into the Contract Development and Manufacturing Organisation (CDMO) segment, according to Managing Director Sanjay Suri. In his message to shareholders in the company’s Annual Report 2026, Suri said Morepen continues to focus on manufacturing high-quality APIs for diverse geographies […]
CW Bureau
·
Sep 2, 2026
GENERAL
Morepen Lab Kicks Off Commercial Execution Of ₹825-Cr CDMO Order
Morepen Laboratories has completed its first commercial dispatch worth ₹50 crore under its ₹825- crore CDMO mandate and expects supplies of around ₹225 crore in Q2 FY2026-27 as it expands manufacturing capacity. Morepen Laboratories Ltd has commenced commercial execution of its recently announced ₹825 crore Contract Development and Manufacturing Organisation (CDMO) mandate by completing its […]
CW Bureau
·
Jul 1, 2026
GENERAL
Morepen Laboratories Q4 PAT Jumps 69%, Revenue Up 22% At ₹472 Cr
Morepen Laboratories, a vertically integrated pharmaceutical and healthcare company, reported a strong performance for Q4 FY26, with net profit rising 69% year-on-year to ₹20 crore, while gross revenue increased 22% YoY to ₹472 crore. The company said revenue growth during the quarter was driven by strong export momentum and continued expansion in its Medical Devices […]
CW Bureau
·
May 27, 2026
